Cellectis (NASDAQ:CLLS) Stock Passes Above Fifty Day Moving Average – Should You Sell?

Shares of Cellectis S.A. (NASDAQ:CLLS) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.92 and traded as high as $4.75. Cellectis shares last traded at $4.66, with a volume of 52,670 shares changing hands.

Analyst Ratings Changes

A number of analysts recently weighed in on CLLS shares. Wall Street Zen upgraded shares of Cellectis to a “hold” rating in a research note on Saturday, September 20th. Barclays increased their target price on shares of Cellectis from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Friday, October 17th. Wells Fargo & Company restated a “positive” rating and issued a $4.00 price target on shares of Cellectis in a research report on Monday, October 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.00.

Cellectis Trading Down 1.1%

The stock has a market capitalization of $259.00 million, a PE ratio of -8.03 and a beta of 2.82. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.63. The business’s fifty day moving average is $3.92 and its 200-day moving average is $2.79.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Friday, November 7th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.11. Cellectis had a negative net margin of 58.06% and a negative return on equity of 51.22%. The firm had revenue of $37.16 million during the quarter, compared to the consensus estimate of $8.22 million. As a group, analysts anticipate that Cellectis S.A. will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellectis

Several institutional investors and hedge funds have recently bought and sold shares of CLLS. Millennium Management LLC raised its position in shares of Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after buying an additional 22,080 shares in the last quarter. Citadel Advisors LLC bought a new stake in Cellectis during the third quarter worth approximately $633,000. Virtu Financial LLC acquired a new position in Cellectis in the third quarter worth approximately $72,000. B Group Inc. raised its position in shares of Cellectis by 0.8% during the third quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock worth $9,352,000 after purchasing an additional 25,000 shares during the period. Finally, Delaney Dennis R purchased a new stake in Cellectis during the third quarter valued at about $68,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.